Navigation Links
Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Date:3/13/2013

Rensselaer, NY (PRWEB) March 13, 2013

The Shingo Prize for Operational Excellence, part of the Jon M. Huntsman School of Business at Utah State University, has selected the Industrial Operations and Product Supply (IOPS) group of Regeneron Pharmaceuticals, Inc. as a recipient of the Shingo Bronze Medallion.

“Receipt of the Shingo Bronze Medallion signifies an organization’s strong use of tools and techniques for business improvement,” said Robert Miller, executive director of The Shingo Prize. “Those organizations that receive the Bronze Medallion are working to develop effective systems to create continuity and consistency throughout the business entity and are on their way to true operational excellence.”

Regeneron purchased the Rensselaer site in 1994 for the purpose of large-scale manufacturing of protein-based pharmaceuticals (biologics). In 2007, Regeneron entered into a collaborative effort with the global healthcare company, Sanofi, to discover and develop antibodies using the Regeneron VelocImmune™ technology and to advance several of these drug candidates into clinical development each year. The IOPS plant at Rensselaer was tasked with increasing its manufacturing output from one or two products to 15-30 bulk products and over 100 final product forms in less than five years. In order to successfully meet the requirements, the Rensselaer site had to respond with significant operations modifications and improvements. It now has the ability to produce as many as five different drug candidates simultaneously or more than 20 in a single year, placing it among the top 15 biopharmaceutical facilities worldwide in terms of production capacity.

“As I reflect back on the last six years, I can’t help but marvel at our progress,” said Daniel P. Van Plew, senior vice president and general manager of Industrial Operations and Product Supply. “Being recognized for our efforts is for sure exciting, but not as exciting as watching this journey continue to unfold a little more each day.”

Through its operations initiatives, the IOPS group at Rensselaer has experienced, among other achievements, a 200% increase in labor productivity, a 92% decrease in product changeover time and a more than 800% increase in the number of product forms manufactured.

Regeneron’s IOPS group will receive the Shingo Bronze Medallion at the Awards Ceremony and Gala during the 25th Annual Shingo Prize International Conference, May 6-10, 2013 in Provo, Utah. The awards gala is the conclusion to this four-day event featuring a selection of workshops, plant tours, keynote speakers and breakout sessions designed to provide ongoing knowledge, insights and experience for organizations in their pursuit of operational excellence.

“In providing recognition, The Shingo Prize invites organizations to challenge early in their implementation of improvement efforts,” Miller said. “Doing so provides them valuable feedback to help accelerate their implementation. By understanding the principles we teach, organizations can begin to proactively change their culture. Culture is the key to sustainable operational excellence.”

About The Shingo Prize
The Shingo Prize for Operational Excellence is named after Japanese industrial engineer Shigeo Shingo. Dr. Shingo distinguished himself as one of the world’s thought leaders in concepts, management systems and improvement techniques that have become known as the Toyota Business System. Drawing from Dr. Shingo’s teachings, The Shingo Prize helps companies and organizations increase their efficiency and effectiveness by developing cultures that better tap the talents of their employees. It also awards and recognizes organizations that demonstrate exceptional results from applying its philosophy. Those interested in more information or in registering to attend the 25th Annual International Conference may visit http://www.shingoprize.org.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma. Those interested in more information about the company may visit http://www.regeneron.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10524606.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Introducing a New, Easy Way for Industrial Businesses to Join the Online Conversation
6. Global Markets for Enzymes in Industrial Applications
7. Global Markets for Enzymes in Industrial Applications -- Focus on Europe
8. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
9. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
10. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
11. Biomass characterization technology research highlighted in Industrial Biotechnology journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, ... offer. This includes buy three, get the fourth unit free with no limit ... derived exosomes, known as exosomes, have been a game changer for regenerative therapies. ...
Breaking Biology Technology:
(Date:7/22/2020)... ... July 21, 2020 , ... ... in technology and compliance, announces a new solution to manage regulated workloads on ... layer of their technology stack complies with FDA and global regulations. USDM's new ...
(Date:7/18/2020)... ... , ... Commercial launch readiness is a critical stage in a product life ... vaccine, the global economic downturn will only increase price pressures overall for the industry. ... full value from every product launch is critical. However, history shows that only a ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient ... that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of ... 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting ...
Breaking Biology News(10 mins):